Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  AB Science    AB   FR0010557264

AB SCIENCE

(AB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
11/30/2020 12/01/2020 12/02/2020 12/03/2020 12/04/2020 Date
10.08(c) 10.34(c) 10.4(c) 10.2(c) 10.44 Last
337 417 83 189 149 494 66 353 387 246 Volume
+1.31% +2.58% +0.58% -1.92% +2.35% Change
More quotes
Financials
Sales 2020 1,80 M 2,19 M 2,19 M
Net income 2020 - - -
Net Debt 2020 - - -
P/E ratio 2020 -
Yield 2020 -
Sales 2021 2,00 M 2,43 M 2,43 M
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 457 M 555 M 555 M
Capi. / Sales 2020 254x
Capi. / Sales 2021 229x
Nbr of Employees 93
Free-Float 55,3%
More Financials
Company
AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals. 
Sector
Pharmaceuticals
Calendar
05/03Earnings Release
More about the company
All news about AB SCIENCE
02:22aAB SCIENCE : announces that confirmatory Phase 3 study AB12005 with masitinib in..
AQ
11/30SCIENCE : Signature of a 15.0 million financing deal with the European Investmen..
PU
11/30SCIENCE : EIB supports AB Science in its COVID-19 development programme
GL
11/23SCIENCE : Equity financing for a maximum of 4 million shares with Alpha Blue Oce..
PU
11/16AB SCIENCE : secures equity financing for a maximum of 4 million shares with Alp..
AQ
11/16SCIENCE : AB Science secures equity financing for a maximum of 4 million shares ..
GL
10/29SCIENCE : Financing of 4.5 million euros through the issuance of bonds convertib..
PU
10/29AB SCIENCE : announces a financing of 4.5 million euros through the issuance of ..
AQ
10/29SCIENCE : AB Science announces a financing of 4.5 million euros through the issu..
GL
10/20AB SCIENCE : announces positive top-line Phase 3 results for oral masitinib in s..
AQ
10/20AB SCIENCE : announces positive top-line Phase 3 results for oral masitinib in s..
AQ
10/20SCIENCE : AB Science announces positive top-line Phase 3 results for oral masiti..
GL
10/20AB Science announces positive top-line Phase 3 results for oral masitinib in ..
GL
10/13SCIENCE : AB Science announces that results from masitinib study AB07015 in seve..
GL
10/13AB SCIENCE : announces that results from masitinib study AB07015 in severe asthm..
AQ
More news
News in other languages on AB SCIENCE
08:04aAB SCIENCE : étude positive en cancer du pancréas
03:04aAB SCIENCE : étude de phase 3 positive pour le masitinib
02:22aSCIENCE : AB Science annonce que l'étude confirmatoire de phase 3 AB12005 avec l..
02:22aAB Science annonce que l'étude confirmatoire de phase 3 AB12005 avec le masit..
11/30AB SCIENCE : la BEI s'intéresse au masitinib
More news
Chart AB SCIENCE
Duration : Period :
AB Science Technical Analysis Chart | AB | FR0010557264 | MarketScreener
Technical analysis trends AB SCIENCE
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 13,00 €
Last Close Price 10,20 €
Spread / Highest target 27,5%
Spread / Average Target 27,5%
Spread / Lowest Target 27,5%
Managers
NameTitle
Alain Moussy Chairman, CEO & Scientific Director
Laurent Guy Chief Financial Officer
Antonello Cervone Director-Information Technology
Catherine Marle Head-Clinical Operations
Jean-Pierre Kinet Director
Sector and Competitors
1st jan.Capitalization (M$)
AB SCIENCE89.59%555
MERCK KGAA30.42%72 586
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD109.20%20 668
KYOWA KIRIN CO., LTD.11.47%14 828
BETTA PHARMACEUTICALS CO., LTD.49.24%5 986
YUHAN CORPORATION37.63%3 565